A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Boys with Duchenne Muscular Dystrophy

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Boys With Duchenne Muscular Dystrophy

Category & Conditions:
Rare Diseases
Medicine:
Domagrozumab (PF-06252616)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B5161002
Open Plain Language Summary Result:Click here